FIBROGEN INC (30) | Intellectual Property (5)
Browse by Subcategory
Recent Contracts
-
Amended and Restated Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of January 21, 2022
(Filed With SEC on May 9, 2022)
-
Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of July 16, 2021
(Filed With SEC on November 9, 2021)
-
Exclusive License and Option Agreement by and between FibroGen, Inc. and HiFiBiO (HK) Limited (D.B.A. HiFiBiO Therapeutics), as of June 16, 2021
(Filed With SEC on August 9, 2021)
-
Second Amended and Restated License, Development and Commercialization Agreement by and among FibroGen China Anemia Holdings, Ltd., FibroGen China Medical Technology Development...
(Filed With SEC on August 6, 2020)
-
Amendment No. 1 to the Amended and Restated License, Development and Commercialization Agreement by and between FibroGen, Inc. and AstraZeneca AB, effective as of July 1, 2020
(Filed With SEC on August 6, 2020)